OMX Ventures — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
Syndexsyndex.bioFeb 2025
Syndex develops mcPCR (methyl copying PCR), a proprietary platform technology that amplifies DNA while preserving methylation patterns, addressing the challenge of low DNA levels in clinical samples.
BiotechDeep TechMedical DevicesSanta Monica, US
Geoff Paul Smith(Executive Officer, Director)Geoff Smith(Founder & CEO)Jason Betley(Chief Product Officer)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.